PUBLISHER: DataM Intelligence | PRODUCT CODE: 1496874
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1496874
Overview
The global bone marrow aspirate concentrates market reached US$ 175.6 million in 2023 and is expected to reach US$ 263.7 million by 2031, growing at a CAGR of 5.3% during the forecast period 2024-2031.
Bone marrow aspirate concentrate (BMAC) is a potentially useful biological product for bone regeneration. Bone marrow concentrate is used in orthopedics as a complement to facilitate mature bone growth. Bone marrow aspirate is a rich source of cells, cytokines, and growth factors, and concentrating the aspirate helps harness the growth factors for bone growth and soft tissue regeneration.
These components are believed to have anti-inflammatory and regenerative properties, making BMAC an innovative treatment for various musculoskeletal conditions, particularly osteoarthritis and cartilage defects. Bone marrow aspirate concentrate is derived from the bone marrow, which is primarily composed of hematopoietic cells, adipose tissue, and supportive stromal cells.
The bone marrow contains a small fraction (0.001% to 0.01%) of mesenchymal stem cells (MSCs), which are crucial for tissue regeneration and repair. BMAC is prepared by centrifuging the aspirated bone marrow to separate the buffy coat, which contains the MSCs and other beneficial components, from the red blood cells and other unwanted elements.
Market Dynamics
Drivers
Increasing Prevalence of Orthopedic Diseases and Sports Injuries
The demand for the global bone marrow aspirate concentrates market is driven by multiple factors. One of the key factors driving the market is the increase in the incidence of sports injuries & orthopedic diseases. In 2024, as per Johns Hopkins Medicine, more than 3.5 million children aged 14 and below sustain sports injuries, which can cause the bones to crack.
As per Scientific Reports research publication in February 2024, patients with knee osteoarthritis who receive platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC) injections have better outcomes than patients who receive hyaluronic acid.
BMA is a rich source of various cellular and molecular components that have demonstrated positive effects on tissue regeneration in musculoskeletal injuries. This increases Tactoset's commercial reach by combining BMA with Tactoset for the treatment of bone defects such as osteoporotic bone, cysts, and insufficiency fractures.
For instance, in January 2023, RegenOrthoSport announced that it had obtained all necessary regulatory approvals from the National Ethics Committee Registry for Biomedical and Health Research (NECRBHR) under the Ministry of Health and Family Welfare for carrying out combination therapies on patients affected with Musculoskeletal Disorders (MSD).
Autologous BMAC-PRP combination approach on MSD patients who are suffering from arthritis, ligament tears, sprains, strains, and sports injuries.
Restraints
Factors such as the limited availability of donors, the high failure rate of the treatment, the lack of skilled professionals, the high cost of production, and stringent regulatory requirements are expected to hamper the market.
For more details on this report - Request for Sample
The global bone marrow aspirate concentrates market is segmented based on product type, application, end-user, and region.
The orthopedic surgery segment accounted for approximately 37.5% of the global bone marrow aspirate concentrates market share
The orthopedic surgery segment is expected to hold the largest market share over the forecast period owing to the increasing number of musculoskeletal disorders and the innovations in treating such disorders. There has been a rise in the number of osteoporosis cases worldwide.
According to the Journal of Climacteric publication in January 2022, osteoporosis causes more than 8.9 million fractures worldwide, resulting in an osteoporotic fracture every 3 seconds. The publication indicated that osteoporosis affected 200 million women worldwide as of January 2022. The large number of people affected by bone disorders is expected to add to the market growth.
Bone marrow aspirate concentrate (BMAC) is now commonly used in orthopedic surgery. Recent studies showed promising results for cartilage, bone, and soft tissue healing, however, many of these outcomes have yet to be translated into human models. While there has been an increase in the use of BMAC in foot and ankle procedures, the associated clinical evidence is limited.
Similarly, in April 2022, EurekAlert new release states that the regenerative potential of solid bone marrow aspirate concentrate is a new study compares the regenerative potential of blood/bone marrow aspirate concentrates obtained from arterial blood, venous blood, and bone marrow aspirate. Blood concentrate material such as platelet-rick fibrin (PRF) is used in clinical practice to promote tissue regeneration in the fields of dentistry, orthopedic surgery, and plastic surgery.
In addition, major key players in the industry launching innovative treatments would propel this segment's growth. For instance, in May 2024, the hospital for special surgery launched a clinical trial that will evaluate the efficacy of concentrated bone marrow aspirate can preventing chronic inflammation and osteoarthritis in ACL revision.
North America accounted for approximately 42.3% of the global bone marrow aspirate concentrates market share
North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of osteoarthritis diseases, technological advancements, and government awareness initiatives that drive this market growth in this region.
In the U.S., Arthritis is a serious health crisis. CDC estimates in 2024, 1 in 5 (or 53.2 million) U.S. adults have some form of arthritis. While there are estimated to be more than 100 types of arthritis, osteoarthritis (OA) is the most common form of arthritis, affecting 32.5 million U.S. adults.
Moreover, key player innovative studies related to BMAC and launch in the region help to drive this market growth. For instance, in April 2022, the general hospital corporation study stated that the bone marrow aspirate promising for treating hip arthroscopy.
This study compared two strategies for preserving full-thickness chondral flaps during hip arthroscopy microfracture, and the use of bone marrow aspirate concentrate to bridge the chondral flap to the subchondral bone Both the microfracture and bone marrow aspirate concentrate (BMAC) cohorts experienced significant improvements in International Hip Outcome Tool-33 (iHOT-33) scores from baseline to the 12-month follow-up visit.
Also, in June 2022, Royal Biologics announced the FDA 510K regulatory clearance and U.S. commercial launch of the MAYY -BMC system. This system is a bone marrow aspirate concentration system that provides users with an optimal sample of concentrated bone marrow aspirate, from a patient, point of care.
The COVID-19 pandemic significantly impacted the global bone marrow aspirate concentrates market. In COVID-19 patients, bone marrow aspirate shows histiocytic proliferation with hemophagocytosis.
Several elective and non-urgent surgeries and therapies were either postponed or canceled, which negatively affected the growth of the bone marrow aspirate concentrate market. For instance, an article published in the Annals of Rheumatic Diseases in January 2021 indicated that during the COVID-19 pandemic, people with musculoskeletal disorders were advised not to seek emergency treatment because of fear of getting contaminated with the SARS-Cov-2 virus.
The major global players in the bone marrow aspirate concentrate market include Zimmer Biomet, Terumo BCT, Inc., Zoetis Services LLC, Arthrex, Inc., Globus Medical, Royal Biologics, Regen Lab SA, AcCellerated Biologics, Isto Biologics, Stryker among others.
The global bone marrow aspirate concentrates market report would provide approximately 62 tables, 53 figures, and 182 Pages.
Target Audience 2024
LIST NOT EXHAUSTIVE